UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

The New England journal of medicine, 2016-11, Vol.375 (19), p.1823-1833

2016

Volltextzugriff (PDF)

Cisplatin or carboplatin in the treatment of non-small cell lung cancer: a comprehensive review

Oncology reviews, 2011-12, Vol.1 (3), p.162-169

2011

Volltextzugriff (PDF)

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC

The New England journal of medicine, 2023-11, Vol.389 (20), p.1839-1850

2023

Volltextzugriff (PDF)

First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status

European journal of cancer (1990), 2020-05, Vol.130, p.155-167

2020

Volltextzugriff (PDF)

Emerging Novel Therapeutic Approaches for Treatment of Advanced Cutaneous Melanoma

Cancers, 2022-01, Vol.14 (2), p.271

2022

Volltextzugriff (PDF)

Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non–small cell lung cancer treated with first-line pembrolizumab

European journal of cancer (1990), 2021-06, Vol.150, p.99-107

2021

Volltextzugriff (PDF)

Predictive and Prognostic Significance of Neuron-specific Enolase (NSE) in Non-small Cell Lung Cancer

Anticancer research, 2008-01, Vol.28 (1B), p.507-513

2008

Volltextzugriff (PDF)

Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non–Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis

JNCI : Journal of the National Cancer Institute, 2007-06, Vol.99 (11), p.847-857

2007

Volltextzugriff (PDF)

Multifactorial Central Nervous System Recurrence Susceptibility in Patients With HER2-Positive Breast Cancer: Epidemiological and Clinical Data From a Population-Based Cancer Registry Study

Cancer, 2011-05, Vol.117 (9), p.1837-1846

2011

Volltextzugriff (PDF)

Distinguishing between immune-related pneumonitis and disease progression in advanced Non Small Cell Lung Cancer treated with PD-1 inhibitors: Can serum tumour markers have a role?

European journal of cancer (1990), 2018-05, Vol.95, p.127-129

2018

Volltextzugriff (PDF)

Prognostic role of hyponatremia in 564 small cell lung cancer patients treated with topotecan

Lung cancer (Amsterdam, Netherlands), 2014-10, Vol.86 (1), p.91-95

2014

Volltextzugriff (PDF)

Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy

Cancer Immunology, Immunotherapy : CII, 2024-10, Vol.73 (12), p.246, Article 246

2024

Volltextzugriff (PDF)

Gain of FGF4 is a frequent event in KIT/PDGFRA/SDH/RAS‐P WT GIST

Genes chromosomes & cancer, 2019-09, Vol.58 (9), p.636-642

2019

Volltextzugriff (PDF)

The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy

Cancers, 2022-11, Vol.14 (23), p.5845

2022

Volltextzugriff (PDF)

Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes

Cancers, 2022-07, Vol.14 (14), p.3472

2022

Volltextzugriff (PDF)

IFN-γ and CD38 in Hyperprogressive Cancer Development

Cancers, 2021-01, Vol.13 (2), p.309

2021

Volltextzugriff (PDF)

Adaptive Individualized high-dose preoperAtive (AIDA) chemoradiation in high-risk rectal cancer: a phase II trial

European journal of nuclear medicine and molecular imaging, 2023-01, Vol.50 (2), p.572-580

2023

Volltextzugriff (PDF)

Activity and safety of dose‐adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor‐prognostic untreated diffuse large B‐cell non‐Hodgkin lymphoma

Cancer, 2011-03, Vol.117 (5), p.964-973

2011

Volltextzugriff (PDF)

Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC)

Lung cancer (Amsterdam, Netherlands), 2014-02, Vol.83 (2), p.265-271

2014

Volltextzugriff (PDF)

Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancer

Journal for immunotherapy of cancer, 2020-10, Vol.8 (2), p.e000502

2020

Volltextzugriff (PDF)

Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer

Cancer, 2006-12, Vol.107 (12), p.2842-2849

2006

Volltextzugriff (PDF)

Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab

Immunotherapy, 2018-06, Vol.10 (8), p.681-694

2018

Volltextzugriff (PDF)

Tumor Growth Rate Decline despite Progressive Disease May Predict Improved Nivolumab Treatment Outcome in mRCC: When RECIST Is Not Enough

Cancers, 2021-07, Vol.13 (14), p.3492

2021

Volltextzugriff (PDF)

Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed–carboplatin

Lung cancer (Amsterdam, Netherlands), 2012-10, Vol.78 (1), p.92-99

2012

Volltextzugriff (PDF)

Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): Study of a comprehensive panel of molecular markers

Lung cancer (Amsterdam, Netherlands), 2010-03, Vol.67 (3), p.355-360

2010

Volltextzugriff (PDF)

26 – 50 von 60

Suche als RSS-Feed

Aktive Filter

Nur zeigenMit Volltextzugriff

ThemaTumors

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(59)

Publikationsform

Artikel
(60)

Sprache

Englisch
(60)

Erscheinungsjahr

n.n

Thema

Science & Technology
(58)
Life Sciences & Biomedicine
(55)
Oncology
(53)
Humans
(46)
Biological And Medical Sciences
(30)
Medical Sciences
(30)
Aged
(28)
Female
(28)
Middle Aged
(27)
Male
(24)
Lung Neoplasms - Drug Therapy
(22)
Pneumology
(21)
Tumors Of The Respiratory System And Mediastinum
(21)
Adult
(20)
Chemotherapy
(20)
Lung Cancer
(19)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(18)
Lung Neoplasms - Pathology
(18)
Aged, 80 And Over
(17)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Lung Cancer
(11)
Journal Of Clinical Oncology
(6)
Cancers
(5)
Cancer
(4)
European Journal Of Cancer
(4)
Plos One
(3)
The New England Journal Of Medicine
(2)
Annals Of Oncology
(1)
Anticancer Research
(1)
Breast Cancer Research And Treatment
(1)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Cisplatin or carboplatin in the treatment of non-small cell lung cancer: a comprehensive review

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC

First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status

Emerging Novel Therapeutic Approaches for Treatment of Advanced Cutaneous Melanoma

Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non–small cell lung cancer treated with first-line pembrolizumab

Predictive and Prognostic Significance of Neuron-specific Enolase (NSE) in Non-small Cell Lung Cancer

Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non–Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis

Multifactorial Central Nervous System Recurrence Susceptibility in Patients With HER2-Positive Breast Cancer: Epidemiological and Clinical Data From a Population-Based Cancer Registry Study

Distinguishing between immune-related pneumonitis and disease progression in advanced Non Small Cell Lung Cancer treated with PD-1 inhibitors: Can serum tumour markers have a role?

Prognostic role of hyponatremia in 564 small cell lung cancer patients treated with topotecan

Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy

Gain of FGF4 is a frequent event in KIT/PDGFRA/SDH/RAS‐P WT GIST

The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy

Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes

IFN-γ and CD38 in Hyperprogressive Cancer Development

Adaptive Individualized high-dose preoperAtive (AIDA) chemoradiation in high-risk rectal cancer: a phase II trial

Activity and safety of dose‐adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor‐prognostic untreated diffuse large B‐cell non‐Hodgkin lymphoma

Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC)

Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancer

Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer

Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab

Tumor Growth Rate Decline despite Progressive Disease May Predict Improved Nivolumab Treatment Outcome in mRCC: When RECIST Is Not Enough

Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed–carboplatin

Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): Study of a comprehensive panel of molecular markers

Aktive Filter

Suchergebnisse filtern